Cosh v. Atrium Medical Corporation

Opinion

UsDC sDONY DOCUMENT ELECTRONICALLY FILED UNITED STATES DISTRICT COURT DATE FILED: SOUTHERN DISTRICT OF NEW YORK ,

TINA M. COSH and LESTER A. COSH, Plaintiff, 1;18-cv-08335 (ALC) -against- OPINION & ORDER ATRIUM MEDICAL CORPORATION, Defendant. ANDREW L. CARTER, JR., United States District Judge: Plaintiffs Tina. M. Cosh (“Mrs. Cosh”) and Lester A. Cosh (collectively, the “Plaintiffs’’) bring this action against Defendant Atrium Medical Corporation (“Defendant”). In short, Plaintiffs allege that Ms. Cosh sustained injuries as a result of the implantation of the Atrium ProLite™ Mesh (“ProLite Mesh”) during her hernia repair surgery in February of 2015. See Am. Compl., ECF No. 13. Specifically Plaintiffs bring the following claims: Strict Liability Design Defect (Count I), Strict Liability Manufacturing Defect (Count I), Strict Liability Failure to Warn (Count III), Negligence (Count IV), Breach of Warranty (Count V), Punitive Damages (Count VI), Fraudulent Misrepresentation (Count VID, Negligent Misrepresentation (Count VUI), Unjust Enrichment (Count IX), Consumer Fraud (Count X), and Loss of Consortium (Count XI). Before the Court is Defendant’s motion to dismiss Plaintiffs’ claims. ECF No. 41. After careful consideration, Defendant’s motion to dismiss is GRANTED. Additionally, Plaintiffs are GRANTED leave to amend their complaint. BACKGROUND! “A hernia is a medical condition caused by the penetration of fatty tissue, intestine, or organs through a weakened or compromised location in muscle of connective tissue.” Am.

' The following facts are drawn from Plaintiffs’ Amended Complaint and are taken as true for the purposes of this motion to dismiss.

Compl. P 19. Typically, hernias occur near the abdominal wall and at times, manifest as visible protrusions or bulges. Jd. P 21. Hernias can be treated through hernia repair surgeries. Jd. |P 22. During such procedures, physicians may utilize hernia mesh, which is constructed from synthetic or biologic materials and tissues, to strengthen the repair. Jd. P 24-25. Common injuries resulting from surgeries using hernia mesh include “pain, infection, adhesion of scar tissue sticking together, blockages that obstruct intestines, internal bleeding, fistula between organs (abnormal organ connection or fusion), serenoma or fluid buildup at site, and perforation of other organs.” Id. P 28. Defendant designed, manufactured, advertised, and sold, the ProLite Mesh, which is a mid-weight polypropylene hernia mesh product. /d. 33-36. Defendant advertised that the ProLite Mesh was safe and effective for hernia repair surgeries. /d. 41. Defendant also advertised the ProLite Mesh as having “[s]oft knit construction,” “[f]lexib[ility] and comfort[],” and “[s|]mooth, laser round edges.” Jd. |P 37-38. On February 5, 2015, Dr. Moaz W. Albulfaraj performed a hernia repair procedure on Mrs, Cosh. Jd, P 53. During this procedure, Dr. Albulfaraj implanted Defendant’s ProLite Mesh from Lot No. 107312426. Jd. Subsequently on Mach 17, 2015, Mrs. Cosh underwent a second surgery to repair a debridement of a nonhealing wound and remove the infected mesh. Id. 55. Since the surgeries, Mrs. Cosh has experienced stomach pains that were not previously present prior to the implantation of Defendant’s ProLite Mesh. Plaintiff alleges that as a result of Defendant’s misrepresentations and omissions concerning the product’s safety, she has suffered economic damages, severe injuries, emotional distress and mental anguish. Jd. P58.

STANDARD OF REVIEW

- When considering a motion to dismiss under Federal Rules of Civil Procedure 12(b)(6), a court should “draw all reasonable inferences in [the plaintiff’s] favor, assume all well-pleaded factual allegations to be true, and determine whether they plausibly give rise to an entitlement to relief.” Faber v. Metro. Life Ins. Co., 648 F.3d 98, 104 (2d Cir. 2011) (internal quotation marks omitted). Thus, “[t]o survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’’’ Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). The Court’s function on a motion to dismiss is “not to weigh the evidence that might be presented at a trial but merely to determine whether the complaint itself is legally sufficient.” Goldman v. Belden, 754 F.2d 1059, 1067 (2d Cir. 1985). The Court should not dismiss the complaint if the plaintiff has stated “enough facts to state a claim to relief that is plausible on its face.” Twombly, 550 U.S. at 570. “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Jgbal, 556 U.S. at 678. Moreover, “the tenet that a court must accept a complaint’s allegations as true is inapplicable to threadbare recitals of a cause of action’s elements, supported by mere conclusory statements.” /d. at 663. DISCUSSION I. Strict Liability and Negligence Claims Here, Plaintiffs bring product liability claims under both strict liability—specifically, counts I, II and Il—and negligence—specifically, count 1V. Under New York law, strict liability and negligence are functionally equivalent. See, e.g., Colon ex rel. Molina v. BIC USA, Inc., 199 F. Supp. 2d 53, 85 (S.D.N.Y. 2001) (citing Caprara v. Chrysler Corp., 52 N.Y.2d 114, 129,

3 .

(1981)) (analyzing strict liability and negligent manufacturing defect claims together); Estrada v. Berkel Inc., 789 N.Y.S.2d 172, 173 (N.Y. App. Div. 2d Dep’t 2005) (“Where liability is predicated on a failure to warn, New York views negligence and strict liability claims as equivalent[.]”) (citation omitted); Searle v. Suburban Propane Div. of Quantum Chem. Corp., 700 N.Y.S.2d 588, 591 (N.Y. App. Div. 3d Dep’t 2000) (‘[I]n a design defect case, there is almost no difference between a prima facie case in negligence and one in strict liability.”). Accordingly, the Court will analyze Plaintiffs’ strict liability and negligence claims of design defects, manufacturing defects, and failure to warn together. a. Design Defect “Under New York law, a plaintiff establishes a prima facie case of products liability for a design defect by showing: (1) that the product, as designed, posed a substantial likelihood of harm; (2) that it was feasible for the manufacturer to design the product in a safer manner; and (3) that the defective design was a substantial factor in causing plaintiffs injury.” See Am. Guarnatee & Liab. Ins. Co. v. Cirrus Design Corp., No. 09-CV-8357, 2010 WL 5480775, at *3 (S.D.N.Y. Dec. 30, 2010) (citing Tuosto v. Philip Morris USA Inc.,672 F.Supp.2d 350, 364 (S.D.N.Y, 2009)). “Although a plaintiff need not possess specialized scientific or technical knowledge at the pleading stage, courts have routinely dismissed strict products liability claims premised on a design defect where the plaintiff has failed to plead that it was feasible to design the product in a safer manner (‘a feasible alternative design’).” Kennedy v. Covidien, LP, No. 18- CV-01907, 2019 WL 1429979, at *3 (S.D.N.Y. Mar. 29, 2019) (citing DiBartolo v, Abbott Labs., 914 F.Supp.2d 601, 622-23 (S.D.N.Y. 2012)); See also Am. Guarnatee, 2010 WL 5480775, at *3 (citing Rypkema v. Time Mfg. Co., 263 F.Supp.2d 687, 692 (S.D.N.Y.2003)) (“When applying this risk-utility balancing test, a plaintiff is required to prove the existence of a

feasible alternative design which would have prevented the accident.”); Voss v. Black & Decker Mfg. Co., 59 N.Y.2d 102, 108 (1983) (“The plaintiff, of course, is under an obligation to present evidence that the product, as designed, was not reasonably safe because there was a substantial likelihood of harm and it was feasible to design the product in a safer manner.”). Here, Plaintiffs have failed to adequately plead a claim of defective design because they have not sufficiently pled the existence of a feasible alternative design. In fact, Plaintiffs’ Amended Complaint includes conclusory statements such as the following: “[a]lternative designs for hernia mesh products and/or procedures existed that were and/or are less dangerous and equally, i[f] not more, effective,” “[a]lternative designs for hernia mesh products and/or procedures existed that were and/or are less dangerous and equally, i[f] not more, effective, including the use of polycarbonate and polystyrene as alternatives,” and “[s]afer and more effective alternatives to hernia mesh exist and have existed since the introduction of hernia mesh products into the market . . . [including] the Shouldice Repair, McVay Repair, Bassini Repair, and Desarda Repair.” Am. Compl., P 32, 72-73. “Simply asserting that a feasible alternative design exists — without pleading any supporting facts — is not sufficient to plead a defective design claim or to put Defendant on notice as to what that design might be.” Green v. Covidien LP, No. 18 CIV. 2939, 2019 WL 4142480, at *3 (S.D.N.Y. Aug. 30, 2019). Furthermore, even if Plaintiff had sufficiently shown that using polycarbonate and polystyrene materials would be technically and economically feasible and result in a safer design, these claims would fail. As courts in this circuit have noted, “alleging that the product should not be used at all is insufficient to satisfy the feasible alternative design element.” Green, 2019 WL 4142480, at *3 (citing Kennedy, 2019 WL 1429979, at *4); see also Dunham y.

Covidien LP, No. 19 CIV. 2851, 2019 WL 2461806, at *2 (S.D.N.Y. May 22, 2019) (dismissing a similar design defect claim in a hernia mesh products liability case), b. Manufacturing Defect Under New York Law, “[t]o plead and prove a manufacturing flaw under either negligence or strict liability, the plaintiff must show that a specific product unit was defective as

a result of ‘some mishap in the manufacturing process itself, improper workmanship, or because defective materials were used in construction,’ and that the defect was the cause of plaintiffs injury.” Am, Guarnatee, 2010 WL 5480775, at *3 (quoting Colon ex rel. Molina v. BIC USA, Inc., 199 F.Supp.2d 53, 85 (S.D.N.Y.2001)). “Where the plaintiff does not allege a specific flaw in the defective unit, New York law allows the use of circumstantial evidence to establish a manufacturing defect when plaintiff can show that the product did not perform as intended and excludes all other causes for the product failure that are not attributable to the defendant.” Kennedy, 2019 WL 1429979, at *4 (citing Goldin v. Smith & Nephew, Inc., No. 12-civ-9217, 2013 WL 1759575 *3 (S.D.N.Y. April 24, 2013)). In this case, Plaintiffs have failed to allege a manufacturing defect. In fact, Plaintiffs have failed to identify what specific component of the device was defective and have failed to adequately allege any deviations from the manufacturing process, improper workmanship, or defective materials. Plaintiffs additionally cannot use Mrs. Cosh’s injuries as circumstantial evidence to establish a manufacturing defect. As Plaintiffs indicate, Mrs. Cosh’s injuries are consistent with “common injuries” and are “known side effects” caused by hernia repair surgeries using mesh products. Am. Compl. P 28. It therefore cannot be said that her ProLite Mesh did not perform as intended. See Kennedy, 2019 WL 1429979, at *4 (dismissing a similar manufacturing defect claim in a hernia mesh products liability case and finding that Plaintiffs

.

common injuries led “to the inference that the product was manufactured and performed as intended”); see also Dunham, 2019 WL 2461806, at *2; Green, 2019 WL 4142480, at *3-4. c. Failure to Warn In order to recover under a failure to warn theory, a claimant must show: “(1) that a manufacturer has a duty to warn; (2) against dangers resulting from foreseeable uses about which it knew or should have known; and (3) that failure to do so was the proximate cause of harm.” Am. Guarnatee, 2010 WL 5480775, at *3 (quoting Colon ex rel. Molina, 199 F. Supp. 2d at 84). As part of satisfying those elements, a plaintiff is “required to prove that the product did not contain adequate warnings.” Mulhall v. Hannafin, 841 N.Y.S.2d 282, 285 (N.Y. App. Div. 1st Dep’t 2007). Generally, whether a warning is adequate is an issue of fact to be determined at trial. Figueroa v. Boston Sci. Corp., 254 F. Supp. 2d 361, 370 (S.D.N.Y. 2003) (quoting Fane v. Zimmer, Inc., 927 F.2d 124, 130 (2d Cir. 1991)). “There are several important considerations that directly affect the adequacy of a warning, including the location and conspicuousness of the warning and the method in which the warning is communicated to the ultimate user.” Anderson

v. Hedstrom Corp., 76 F. Supp. 2d 422, 440 (S.D.N.Y. 1999). Here, Plaintiffs’ allegations of inadequate warnings are, for the most part, conclusory. For example, Plaintiffs allege the device “contained warnings which were inadequate and insufficient to alert physicians or consumers to the dangerous risks associated with the product” and that “(tlhe warnings ... were ambiguous or were not sufficient, accurate or clear.” Am, Compl. P 98, 104. Plaintiffs further allege, Atrium’s website “has a very minimal amount of advertisement and information for the general public.”* Jd. P 99. Notably absent from Plaintiffs’ Amended Complaint is the exact language of the warnings contained on the device. The Court therefore

2 To support this allegation, Plaintiffs cite to Atrium’s website. See Am. Compl. |P 99, (citing http://www.atriummed,.com/en/biosurgery/prolite.asp). However, this webpage is no longer accessible.

finds, Plaintiffs’ “allegations do not include any factual content regarding . . . how the provided warnings and information failed to [ Jaccurately reflect[ ] reality; they do not provide a plausible basis to support an inference that [Defendant] misrepresented anything.” Green, 2019 WL 4142480, at *5 (S.D.N.Y. Aug. 30, 2019) (quoting Reed v. Pfizer, Inc., 839 F. Supp. 2d 571, 576 (E.D.N.Y. 2012)); see also Dunham, 2019 WL 2461806, at *3; Kennedy, 2019 WL 1429979, at *5, Accordingly, this claim must be dismissed. Il. Fraud Based Claims a. Fraudulent Misrepresentation To state a claim for fraudulent misrepresentation under New York law, a plaintiff must show: “(1) the defendant made a material false representation, (2) the defendant intended to defraud the plaintiffs thereby, (3) the plaintiffs reasonably relied upon the representation, and (4) the plaintiffs suffered damage as a result of their reliance.” Swersky v. Dreyer & Traub, 643 N.Y.S.2d 33, 36 (N.Y. App. Div. Ist Dep’t 1996). To satisfy the element of damage, a Plaintiff must establish proximate causation. Jn re Fosamax Prods. Liab. Litig., 924 F. Supp. 2d 477, 489 (S.D.N.Y. 2013); see, e.g., Hunt v. Enzo Biochem, Inc., 471 F. Supp. 2d 390, 399-400 (S.D.N.Y. 2006) (stating that a claim of common law fraud under New York law “requires a showing of proximate causation”). Additionally, fraudulent misrepresentation claims are subject to the heightened pleading standards of Federal Rule of Civil Procedure 9(b), which provides that “[i]n alleging fraud or mistake, a party must state with particularity the circumstances constituting fraud or mistake.” Fed. R. Civ. P. 9(b); To comply with Rule 9(b), a complaint alleging fraudulent misrepresentation under New York law must: “(1) specify the statements that the plaintiff contends were fraudulent, (2) identify the speaker, (3) state where and when the statements were

made, and (4) explain why the statements were fraudulent.” Lerner v. Fleet Bank, N.A., 459 F.3d 273, 290 (2d Cir. 2006) (quoting Mills v. Polar Molecular Corp., 12 F.3d 1170, 1175 (2d Cir. 1993)). “A statement is ‘fraudulent’ if it was falsely made, or caused to be made, with the intent to deceive.” United States v. Sabbeth, 262 F.3d 207, 217 (2d Cir. 2001) (citations omitted). Plaintiffs’ fraudulent misrepresentation claims largely fall into two categories. First, Plaintiffs allege Defendant fraudulently made misrepresentations from 2009 to present, concerning the safety of the Prolite Mesh. See Am. Compl. |P 136, 139; 151-153; 158. Second, Plaintiffs allege from 2009 to present Defendant omitted material information from their website, instructions for use, literature to the medical community, advertisements, and brochures, concerning the risks associated with the device. See Am. Compl. P 140-50; 153, 155-57.3 The Court finds that both types of claims fail. As an initial matter, Plaintiffs’ allegations premised upon affirmative misrepresentations fail to sufficiently satisfy Rule 9(b). In particular, Plaintiffs’ Amended Complaint only specifies affirmative statements from the product brochure. See Am. Compl. PP 139 (“Atrium’s website explicitly warrants Defendant’s device as having ‘See-thru clarity’, ‘Flexible and comfortable,’ and ‘smooth.’”), However, Plaintiffs fail to explain why the statements are fraudulent and therefore these claims must be dismissed. See Dunham, 2019 WL 2461806, at *4 (‘Absent any factual support for the conclusion that [the defendant’s] statements regarding the hernia mesh were fraudulent, the fraudulent misrepresentation claim cannot stand.”); see also Green,2019 WL 4142480, at *9; Kennedy, 2019 WL 1429979, at *7, In addition, Plaintiffs’ allegations premised on omissions fail to allege reliance because the Amended Complaint lacks details regarding whether and how Mrs. Cosh and her physician

3 Again, Plaintiffs support their allegations by citing to various webpages on Defendant’s website. See Am. Compl. 137-40. With the exception of the Product brochure, the remaining webpages are no longer available. Id.

reviewed and relied upon Defendant’s statements. Instead, Plaintiffs make conclusory allegations such as “Plaintiff TINA COSH, through her physicians and healthcare providers, and her physicians reasonably relied upon Atrium’s misrepresentations and omissions regarding the safety and efficacy of Atrium’s hernia mesh product.” See e.g., Am. Compl. 163. Because Plaintiffs fail to provide factual support showing what information Mrs. Cosh and her treating physician received and whether or not they relied on those statements, Plaintiffs have failed to sufficiently plead a claim of fraudulent misrepresentations based on omissions. Quintana v. B. Braun Med. Inc., No. 17-CV-06614 (ALC), 2018 WL 3559091, at *8 (S.D.N.Y. July 24, 2018), appeal withdrawn, No. 18-2495, 2018 WL 6167320 (2d Cir. Oct. 19, 2018). For the aforementioned reasons, Plaintiffs’ fraudulent misrepresentation claims are dismissed. b. Negligent Misrepresentation . To state a claim for negligent misrepresentation, a plaintiff must show that: the defendant had a duty, as a result of a special relationship, to give correct information; (2) the defendant made a false representation that he or she should have known was incorrect; (3) the information supplied in the representation was known by the defendant to be desired by the plaintiff for a serious purpose; (4) the plaintiff intended to rely and act upon it; and (5) the plaintiff reasonably relied on it to his or her detriment. Eaves v. Designs for Fin., Inc., 785 F. Supp. 2d 229, 254 (S.D.N.Y. 2011) (quoting Hydro Investors, Inc. v. Trafalgar Power Inc., 227 F.3d 8, 20 (2d Cir. 2000)). “A plaintiff alleging negligent misrepresentation must establish reliance upon a false statement or material misrepresentation or omission, and the learned intermediary rule eliminates the possibility of any such reliance.” Amos v. Biogen Idec Inc., 249 F. Supp. 3d 690, 697 (W.D.N.Y. 2017) (internal citations and quotations marks omitted), Again, because here Plaintiffs fail to sufficiently allege the Defendant made false representations and fail to plausibly allege what misrepresentations Mrs. Cosh or her physician relied on, their negligent

misrepresentation claims are dismissed, See Glidepath Holding B. V. v. Spherion Corp., 590 F. Supp. 2d 435, 459 (S.D.N.Y. 2007) (“[W]hether a plaintiff has adequately pleaded justifiable reliance can be a proper subject for a motion to dismiss in certain circumstances.”); see also Kennedy, 2019 WL 1429979, at *7 (S.D.N.Y. Mar. 29, 2019) (dismissing a negligent representation claim because “Plaintiff d[id] not provide any factual basis for his conclusion that Defendant’s risk disclosures for [the hernia mesh product] were misrepresentations or inaccurate.”). c. Consumer Fraud Section 349 of New York General Business Law makes unlawful “[d]eceptive acts or practices in the conduct of any business, trade or commerce or in the furnishing of any service in this state.” N.Y. Gen. Bus. Law. § 349(a). Section 350 prohibits “[fJalse advertising in the conduct of any business.” N.Y. Gen. Bus. Law § 350. To state a claim for deceptive practices under either section, a plaintiff must show: “(1) that the act, practice or advertisement was consumer-oriented; (2) that the act, practice or advertisement was misleading in a material respect, and (3) that the plaintiff was injured as a result of the deceptive practice, act or advertisement.” Pelman v. McDonald's Corp., 237 F. Supp. 2d 512, 524-25 (S.D.N.Y. 2003). To state a claim under the statute, a plaintiff must, “as a threshold matter, .. . charge conduct of the defendant that is consumer-oriented,” Oswego Laborers' Local 214 Pension Fund v. Marine Midland Bank, MA, defined as conduct that “potentially affect[s] similarly situated consumers.” 85 N.Y.2d 20, 745 (N.Y. 1995), Consumer-oriented conduct does not require a repetition or pattern of deceptive conduct, but a plaintiff must nevertheless “demonstrate that the acts or practices have a broader impact on consumers at large.” Jd. at 744. In addition, “[t]o properly

_ allege causation, a plaintiff must state in his complaint that he has seen the misleading statements

o fwhihcech o mapilbnesfo rheec maein ot posseosftse hip orno dhuepc utrsc hased." GoldembJeorhgn&vs .oJ nnso noh ConsuCmoesInr.c8 ,.F .,S up3pd4. 6 ,47 8(0S .D.N.Y. 2014) (citintienagrl, Gi aalev, .I n tBlu Msa.c Chosr.9p A ..,D .434,d76 8N1Y. .S4.52 (dN .Y. App. 2DdDi evp.2' 0t0 4)).

Int hciasss imeil,ar t ote h discuosnsfa iruoduenlnsmt is erpreenstaatnindeo lging ent miesprresenPltaaitnitoinff,ts oa'l g lefafae icl tsusurpep otrehct oicnnlgu staihttoh enD efendant mademi srepresaenndtht eafiatilriu otrnoaells e ege itMhrseC.ro sohrh erhy spiicarnlei eodn tehses attemiefsna tttsoat leh i crnosmuerf racualdi mte;hs cel atiehmrfoser aerdei smissed. Dunh2a10m9,W L 2 64180a 6t* ,5(d ismiasc snoisnuegmrf raculdaw ihme Prlaien tdii"ffdn ot allesguef fifaccittoess un ptmp ia c nolcusitoh naa ntoyf[ tdhfeeen danrter'pess]e ntwaertei ons deepctiov rfael se."). III.Breach of Warranty a.ExprBersesoa fWc ahr ranty

Ane xprweasrsr iafsno trymb ey"da [] nayffi rmaotffai cootnrp rommiasdbeey t he seltlote hbreu ywehri rcehl taott hegeso oodrs' 'a dneys croiftp htgeio oontd hsia''st p aoifti h e basoifts h e baWriglailni2.a0"m1U's3. o DSni.,s L tE.X I1S0 4424051W,3L 3 833a0t8* 81 , (quoNt.iYn.g U§2. -C3.1CW3.h) ii.lit ens o rte qutiour sefoedr mwaolr sdusca hs" warroarn t" "guarannoatrle lete,hg"tae hts e p eahkaaeds r p eciinftiectn omt aikoaewn a rra"natny , affirmamteiroeonlft y hv ea loufte hg eo oodrass tatepmuernptot robt emi enrget lhsyee ller's opinoirco onm mendoaftt hgieoo ondd osen soc tr eaaw taer raInd."t Tyeo.s "t atbhlbeir seha ch ofa ne xprweasrsr atnhptely a,im nutssithf otfwh tahtew raeas n ' affirmaotffi aoocrpnt r omise byt hsee ltlhenera ,t utreanldo efwn hciyc h [iwnadstu]hcb eeut yote opr u rchaantsdhe ta'ht e warrwaanrste yl uipeotdnot hpel aidnettirffiGsmo elntd2.0i"1nW3 ,L 1 759a5t7* 56(, c iting Barrett v. Black & Decker (U.S.) Inc., No. 06-CV-1970, 2008 WL 5170200, at *12 (S.D.N.Y. Dec. 9, 2008)). In this case, Plaintiff alleges the Defendant warranted that the ProLite Mesh was safe, effective and adequately tested in medical trials. See Am. Compl. PP 126, 151-52, 176. Plaintiffs however fail to identify a specific warranty made by Defendant that was relied upon by Plaintiffs. Kennedy, 2019 WL 1429979, at *6 (citing Viania v. Zimmer, Inc., No. 2:17-cv-164, 2017 WL 5714725, at *5 (E.D.N.Y. Nov. 27, 2017)) (Plaintiff's “characterization of Defendant’s marketing material as generally implying that [the hernia mesh product] was ‘safe and effective’ does not identify any specific actionable conduct or statement on behalf of Defendant.”). Accordingly, Plaintiffs’ express breach of warranty claim must be dismissed. b. Implied Breach of Warranty Under the New York Uniform Commercial Code, “[t]o establish that a product is defective for purposes of a breach of implied warranty of merchantability claim, a plaintiff must show that the product was not reasonably fit for its intended purpose, an inquiry that focuses on the expectations for the performance of the product when used in the customary, usual, and reasonably foreseeable manners.” Porrazzo v. Bumble Bee Foods, LLC, 822 F. Supp. 2d 406, 420-21 (S.D.N.Y. 2011) (citing O'Sullivan v. Duane Reade, Inc., 27 Misc. 3d 1215[A], 910 N.Y.S.2d 763, 2010 NY Slip Op 50757[U] at *6 [N.Y. Sup. Ct. 2010]). For reasons articulated above, Plaintiffs fail to allege that the ProLite Mesh implanted in Mrs. Cosh was not reasonably fit for their intended purpose. “Although the complaint alleges that Mrs. Cosh has experienced stomach pain . . . following his procedures, those allegations of common consequences of hernia surgeries do not show that [Defendants’] products were unsafe for hernia mesh repairs.” Dunham, 2019 WL 2461806, at *5. See also Kennedy, 2019 WL 1429979, at *6 (dismissing an

implied breach of warranty claim where plaintiff did “not allege[] or argue[] a factual basis for concluding that the product was not minimally safe for its expected purpose despite some disclosed risks.”). Plaintiffs’ implied breach of warranty claim therefore must also be dismissed. IV. Unjust Enrichment “To prevail on a claim for unjust enrichment in New York, a plaintiff must establish (1) that the defendant benefitted; (2) at the plaintiff's expense; and (3) that equity and good conscience require restitution.” Beth Israel Med. Ctr v. Horizon Blue Cross & Blue Shield of New Jersey, Inc., 448 F.3d 573, 586 (2d Cir. 2006) (citing Kaye v. Grossman, 202 F.3d 611, 616 (2d Cir.2000)) (internal quotation marks omitted). Because Plaintiffs have neither plausibly pleaded facts supporting a finding that the ProLite Mesh inserted in Plaintiff Mrs. Cosh was defective nor have they pled that the sale of said product was induced by misrepresentations or omissions, restitution is not appropriate. See Kennedy, 2019 WL 1429979, at *8 (dismissing a Plaintiff's unjust enrichment claim in a case involving a hernia mesh because he “ha[d] not plausibly pleaded facts demonstrating that Defendant’s product was defective or that the sale was induced through a misrepresentation, and thus there is no equitable basis for a requiring restitution.”); see also Green, 2019 WL 4142480, at *9; Dunham, 2019 WL 2461806, at *6. V. Punitive Damages In light of the Court’s dismissal of Plaintiffs’ other claims, it is unnecessary for the Court to reach Defendants’ remaining contentions regarding dismissal of Plaintiffs’ prayer for punitive damages, which is not a self-sustaining claim. ACR Sys., Inc. v. Woori Bank, 232 F. Supp. 3d 471, 479 (S.D.N.Y. 2017) (citing Martin v. Dickson, 100 Fed.Appx. 14, 16 (2d Cir, 2004)); see also Green, 2019 WL 4142480, at *10; Kennedy, 2019 WL 1429979, at *8.

VI. Loss of Consortium Similarly, the Court need not address Plaintiffs’ claims for loss of consortium, See Dunham, 2019 WL 2461806, at *6 (S.D.N.Y. May 22, 2019) (citing Jordan v. Lipsig, Sullivan, Mollen & Liapakis, P.C., 689 F. Supp. 192, 196 (S.D.N.Y. 1988)) (“A claim for loss of consortium or services is a derivative action, and in the common law of New York, does not exist ‘independent of the injured spouse’s right to maintain an action for injuries sustained.’”). VII. Leave to Amend Pursuant to Federal Rules of Civil Procedure 15(a)(1) a party may amend its complaint once without leave of court up to 21 days after the service of either a responsive pleading or various Fed. R. Civ. P. 12 motions. See Fed. R. Civ. P. 15(a)(1). After that time has expired, any amendment requires the consent of the opposing parties or leave of court. See Fed. R. Civ. P. 15(a)(2). Rule 15(a)(2) states “the court should freely give leave when justice so requires.” Id. The Supreme Court has instructed that “this mandate is to be heeded.” Foman vy. Davis, 371 U.S. 178, 182 (1962). However, it is ultimately “within the sound discretion of the court whether to grant leave to amend.” John Hancock Mut. Fife Ins. Co. v. Amerford Int'l Corp., 22 F.3d 458, 462 (2d Cir. 1994) (citing Foman, 371 U.S. at 178). Where “the moving party has unduly delayed or acted in bad faith, the opposing party will be unfairly prejudiced if leave is granted, or the proposed amendment is futile” courts in this circuit have denied motions to amend a complaint. Agerbrink v. Model Serv. LLC, 155 F. Supp. 3d 448, 452 (S.D.N.Y. 2016). The Court finds that Defendants have not made a showing of bad faith or prejudice. Accordingly, Plaintiffs are GRANTED leave to amend their Complaint.

CONCLUSION For the foregoing reasons; Defendant’s Motion to Dismiss is GRANTED. However, Plaintiffs are GRANTED leave to amend their complaint. Plaintiffs shall submit an amended complaint to the Court on or before March 5, 2020. SO ORDERED. Dated: February 6, 2020 New York, New York NDREW L. CARTER, JR. United States District Judge